^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BL-M11D1

    i
    Other names: BL-M11D1
    Associations

    News

    Trials
    Company:
    Biokin Pharma
    Drug class:
    Topoisomerase I inhibitor, CD33-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    3d
    A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
    P2/3, N=80, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P2/3 trial
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • BL-M11D1
    2ms
    A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=130, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    BL-M11D1
    4ms
    A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=130, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | N=26 --> 130 | Trial completion date: Aug 2025 --> Dec 2025 | Trial primary completion date: Aug 2025 --> Dec 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    BL-M11D1
    7ms
    Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=120, Recruiting, SystImmune Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BL-M11D1
    1year
    A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-M11D1 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=120, Not yet recruiting, SystImmune Inc.
    New P1 trial
    |
    BL-M11D1
    2years
    A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=26, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BL-M11D1
    over2years
    A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=26, Not yet recruiting, Sichuan Baili Pharmaceutical Co., Ltd.
    New P1 trial
    |
    BL-M11D1